The RSA Group

We #connect elite #lifescience #talent with extraordinary organisations pioneering #medical advances.

[The RSA Group @theRSAgroup]

The BIA’s 2035 vision for UK life sciences emphasises the need to boost late-stage capital and scale up companies to remain globally competitive. Addressing funding gaps and attracting talent will drive growth and innovation to improve global health. https://t.co/7PbrDIUDK0

[The RSA Group @theRSAgroup]

Biosimilars are expanding access to affordable biologic therapies for chronic conditions, with the WHO leading efforts to strengthen regulatory frameworks and global partnerships to improve their availability and quality. Learn more here: https://t.co/Jsjzpt1WBx

[The RSA Group @theRSAgroup]

Chronos-PD, a groundbreaking initiative led by global healthcare leader Grifols, is working to identify early biomarkers of Parkinson’s disease using plasma samples, thus potentially enabling earlier interventions and averting damage. Learn more here: https://t.co/xiV0ZRfj7s .

[The RSA Group @theRSAgroup]

The UK biotech sector raised £3.5B in 2024, a 94% increase from 2023, despite economic and regulatory challenges. The sector stays resilient, driving innovation with promising progress ahead. https://t.co/3om5t5FGvr

[The RSA Group @theRSAgroup]

In a recent Life Science Leader podcast, Dr. Jim Doherty, Ph.D., from Acumen Pharmaceuticals, discusses challenges in Alzheimer's treatment, the role of biomarkers, and the latest advancements in CNS drug development. Listen here: https://t.co/QT9Ha2t7bv

[The RSA Group @theRSAgroup]

The 2025 EY Firepower Report highlights key trends in life sciences dealmaking: while volume remains stable, deal value has decreased. As the industry looks to 2025, companies are shifting focus to smaller, strategic deals. Read the full analysis here: https://t.co/PdFkyvsMrD

[The RSA Group @theRSAgroup]

In January, the biotech sector saw continued momentum in funding, with oncology, obesity, and neurological conditions attracting the most private funding. Oncology remained the leader, with nine funding rounds totalling $507 million. Learn more here: https://t.co/N2SDffgaX6

[The RSA Group @theRSAgroup]

The latest UK #biotech financing report, published by the @BIA_UK, highlights the UK biotech sector's growth, global appeal, and its ability to stay competitive on the global stage 🌍

Read the report here ➡️ https://t.co/tZ72Gv5Dcb

[The RSA Group @theRSAgroup]

In 2024, we saw a wave of groundbreaking biosimilar approvals across various therapeutic areas, such as oncology and rheumatology. These approvals may signal a promising future for greater accessibility and affordability in healthcare. Learn more here: https://t.co/O9asYhh5kI

[The RSA Group @theRSAgroup]

Is biotech mergers and acquisitions (M&A) poised for a surge in 2025? 📈 After a slowdown in 2024, where biotech M&A activity dropped significantly, experts are now anticipating a rebound in 2025. Learn more here: https://t.co/Vj8QxgTS8s

[The RSA Group @theRSAgroup]

Scrip’s latest survey signals a positive outlook for biopharma in 2025, with a focus on transformative therapies & partnerships. As macro conditions stabilise, high-quality companies will attract investment, driving innovation and early-stage development. https://t.co/Id7OYSIWwk

[The RSA Group @theRSAgroup]

Why is 3.5% the magic number for biotech funding? The biotech sector has faced turbulence in recent years due to rising rates and market uncertainty. Experts say once interest rates hit 3.5%, capital costs drop, sparking investor interest and reviving IPOs.

[The RSA Group @theRSAgroup]

Happy New Year from The RSA Group! We wish you happiness, health and success in 2025 🎆✨

[The RSA Group @theRSAgroup]

Merry Christmas from The RSA Group! As we wrap up 2024, we want to express our sincere thanks to our employees, clients, and partners for your continued support.

Wishing you all a joyful and peaceful holiday season 🎄⭐

[The RSA Group @theRSAgroup]

As leaders, the energy we bring shapes our teams and culture. Positive energy fosters trust & innovation, while negative energy drains productivity. Protect your energy to lead effectively. Learn more here on Forbes: https://t.co/eEXRzh4eeP

[The RSA Group @theRSAgroup]

As the push for net-zero grows, pharma is embracing decarbonisation. Future State Planning helps assess emissions and create a roadmap, unlocking innovation, cost savings, and a competitive edge in a climate-conscious market. Learn more here: https://t.co/6NlXIB6R9H

[The RSA Group @theRSAgroup]

What were the biggest private biotech investments globally in November 2024? Oncology, central nervous system and genetic disorder players attracted the biggest funding rounds overall. The top three players were Metsera, Alentis Therapeutics and Adcendo. https://t.co/13E3PVUO2Z

[The RSA Group @theRSAgroup]

In an article on Life Science Leader, Blandine Lacroix, Senior Vice President of Strategy and Rare Disease at Novo Nordisk, reflects on the personal decisions that have shaped her leadership values. Read more here: https://t.co/LUFu0gOrjx

[The RSA Group @theRSAgroup]

Researchers say they have found the first new treatment for asthma attacks in 50 years. The injection of benralizumab targets a type of white blood cell (called an eosinophil) that can cause inflammation and damage in the lungs. Learn more here: https://t.co/LdjTVNy3Zn

[The RSA Group @theRSAgroup]

In a guest column on Life Science Leader, Frank D. Lee, CEO of Pacira BioSciences, shares his three core tenets for life science leaders:
1. Practice high-integrity science.
2. Take care of your people.
3. Redefine what patient-first means.
Learn more: https://t.co/9mYOGKKWtg